Drug Trial Radar · NCT06279130
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations
Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
133
Planned (sponsor's estimate)
Start
Jan 29, 2024
Primary completion
Jan 29, 2029
Study completion Jan 29, 2034
Sponsor
- Lead sponsor
- The Netherlands Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Agenus Inc.
- First posted
- Feb 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, the efficacy of botensilimab and balstilimab in mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) tumors will be assessed.
Conditions
- Resectable MMR-deficient Solid Tumors
- Resectable MMR-proficient Solid Tumors
Interventions
botensilimabDrug
Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)
balstilimabDrug
Anti programmed cell death protein-1 (anti-PD1)
FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)Drug
5-Fluorouracil (2400mg/m2), leucovorin (200mg/m2), oxaliplatin (85mg/m2), docetaxel (50mg/m2).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major pathological response rateTime frame: Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Netherlands Cancer Institute
Amsterdam, North Holland, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.